Cytori Therapeutics Inc (NASDAQ:CYTX) has been assigned a $5.00 price target by equities researchers at Maxim Group in a research note issued on Thursday. The brokerage presently has a “buy” rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the company. B. Riley reissued a “neutral” rating on shares of Cytori Therapeutics in a research report on Wednesday, August 16th. Zacks Investment Research cut Cytori Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. Finally, ValuEngine cut Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st.

Shares of Cytori Therapeutics (NASDAQ:CYTX) opened at 0.486 on Thursday. The company has a 50 day moving average of $0.41 and a 200-day moving average of $0.77. The company’s market cap is $16.87 million. Cytori Therapeutics has a 52 week low of $0.28 and a 52 week high of $2.13.

Cytori Therapeutics (NASDAQ:CYTX) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.02). Cytori Therapeutics had a negative net margin of 450.34% and a negative return on equity of 202.62%. The business had revenue of $0.90 million during the quarter, compared to the consensus estimate of $2.23 million. During the same period in the prior year, the company posted ($0.43) earnings per share. The firm’s revenue was down 18.2% compared to the same quarter last year. On average, equities research analysts expect that Cytori Therapeutics will post ($0.60) earnings per share for the current fiscal year.

WARNING: “Maxim Group Analysts Give Cytori Therapeutics Inc (CYTX) a $5.00 Price Target” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.watchlistnews.com/maxim-group-analysts-give-cytori-therapeutics-inc-cytx-a-5-00-price-target/1640850.html.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Cytori Therapeutics by 81.9% in the second quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock valued at $674,000 after purchasing an additional 275,653 shares in the last quarter. Perkins Capital Management Inc. raised its stake in shares of Cytori Therapeutics by 99.0% in the second quarter. Perkins Capital Management Inc. now owns 874,896 shares of the biotechnology company’s stock valued at $962,000 after purchasing an additional 435,217 shares in the last quarter. Finally, Sabby Management LLC raised its stake in shares of Cytori Therapeutics by 28.0% in the second quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock valued at $1,789,000 after purchasing an additional 355,504 shares in the last quarter. Institutional investors and hedge funds own 11.82% of the company’s stock.

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.